| Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction F Fernández-Avilés, JA San Román, J García-Frade, ME Fernández, ... Circulation research 95 (7), 742-748, 2004 | 622 | 2004 |
| The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease B Díaz‐Agustín, L Escribano, P Bravo, S Herrero, R Nuñez, R Navalón, ... British journal of haematology 106 (2), 400-405, 1999 | 44 | 1999 |
| Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study C Jiménez, MI Prieto-Conde, M García-Álvarez, M Alcoceba, F Escalante, ... Annals of Hematology 97, 475-484, 2018 | 22 | 2018 |
| Oral anticoagulant treatment: risk factors involved in 500 intracranial hemorrhages A Cantalapiedra, O Gutierrez, JI Tortosa, M Ya1ñez, M Dueñas, ... Journal of thrombosis and thrombolysis 22, 113-120, 2006 | 22 | 2006 |
| Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)? L Villalón, AG Avello, J César, J Odriozola, J López, JP Oteyza, JG Laraña, ... Thrombosis research 99 (5), 439-446, 2000 | 22 | 2000 |
| Emphysematous gastritis and severe aplastic anemia. O Gutierrez, A Cantalapiedra, MI Tabuyo, R Del Villar, MJ Peñarrubia, ... The Hematology Journal: the Official Journal of the European Haematology …, 2003 | 21 | 2003 |
| Novel agents as main drivers for continued improvement in survival in multiple myeloma B Puertas, V González-Calle, E Sobejano-Fuertes, F Escalante, ... Cancers 15 (5), 1558, 2023 | 20 | 2023 |
| Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens T Castaño-Bonilla, JM Alonso-Dominguez, E Barragán, ... Scientific Reports 11 (1), 20745, 2021 | 16 | 2021 |
| Phase II trial of ofatumumab plus ESHAP (O‐ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first‐line chemotherapy C Martínez, A Díaz‐López, M Rodriguez‐Calvillo, R García‐Sanz, ... British Journal of Haematology 174 (6), 859-867, 2016 | 14 | 2016 |
| Aspectos prácticos sobre el diagnóstico y tratamiento de las mastocitosis del adulto L Escribano, P Bravo, A Cantalapiedra, R VASQUEZ CARNERO, ... Actas dermo-sifiliográficas (Ed. impresa) 90 (5), 211-223, 1999 | 14 | 1999 |
| Identification of relapse‐associated gene mutations by next‐generation sequencing in low‐risk acute myeloid leukaemia patients MI Prieto‐Conde, C Jiménez, M García‐Álvarez, F Ramos, A Medina, ... British Journal of Haematology 189 (4), 718-730, 2020 | 12 | 2020 |
| Familial occurrence of primary antiphospholipid syndrome A Cantalapiedra, AG Avello, JL Navarro, JM Cesar Thrombosis research 95 (2), 127-129, 1999 | 11 | 1999 |
| Mantle cell lymphoma with amyotrophic lateral sclerosis (motor neuron disease) S Herrero, A Cantalapiedra, J Pérez-Oteyza, C Bellas, J Gobernado, ... Haematologica 83 (4), 382-383, 1998 | 6 | 1998 |
| Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion. MJ Peñarrubia, LA Silvestre, J Conde, A Cantalapiedra, GF LJ Leukemia research 33 (6), e8-9, 2009 | 5 | 2009 |
| Estudio de incidencia de las neoplasias hematopoyéticas en Castilla y León JA Rodríguez-García, L Vázquez, F Ramos, B Cuevas, A Martín, ... Medicina Clínica 144 (11), 491-500, 2015 | 4* | 2015 |
| Primary biliary cirrhosis," sicca" síndrome and autoimmune hemolytic anemia A Cantalapiedra, MJ Penarrubia, O Gutierrez, F Garcia-Pajares, H Nunez, ... Revista Espanola de Enfermedades Digestivas 97 (9), 678-679, 2005 | 4 | 2005 |
| Estado de flujos de efectivo AMT Cantalapiedra Técnica contable 61 (719), 16-25, 2009 | 3 | 2009 |
| Incidence of deep venous thrombosis associated with central venous catheters (DVT-CVC) in cancer patients: A multicenter study J Feliu, R Lecumberri, A Jerez, A Cantalapiedra, T García, E Gonzalez, ... Journal of Clinical Oncology 24 (18_suppl), 8627-8627, 2006 | 3 | 2006 |
| Salvage treatment with ofatumumab and ESHAP (O-ESHAP) for patients with relapsed or refractory classical hodgkin's lymphoma after first-line chemotherapy: interim analysis of a … C Martinez, M Rodriguez-Calvillo, MJ Terol, B Xicoy, R García-Sanz, ... Blood 120 (21), 1630, 2012 | 2 | 2012 |
| Circular 3/2010, de 29 de junio, del banco de españa de modificación de la circular 4/2004 AMT Cantalapiedra Técnica contable 62 (734), 61-69, 2010 | 2 | 2010 |
